Adjusting guselkumab dosing schedules for adults with plaque psoriasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, real-world study of adult patients receiving guselkumab for cutaneous plaque psoriasis, focusing on cases where dosing intervals have already been extended beyond nine weeks. Investigators will collect clinical scores (PASI and IGA) and treatment histories to describe durability of response after interval prolongation and reasons for extension. Patients treated primarily for joint disease or whose extension was driven by surgery, pregnancy, or infection are excluded to keep the analysis focused on dermatologic response. The design builds on prior findings that some "super-responders" can tolerate longer intervals, and aims to document outcomes in routine clinical practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* .Adult patients receiving guselkumab for cutaneous psoriasis. 2.
* Guselkumab treatment with dosing intervals exceeding 9 weeks.

Exclusion Criteria:

* Patients receiving guselkumab primarily for joint involvement.
* Patients for whom guselkumab dosing was extended due to surgery, pregnancy, or infection.
* Patients for whom the PASI or IGA score was not assessed during visits

Where it's running

• CHU de Nice
  Nice, Alpes Maritimes, France Recruiting

Study contacts

• Study coordinator: Thierry PASSERON
• Email: passeron.t@chu-nice.fr
• Phone: 0492036225

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care

  This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.

  Recruiting Janssen-Cilag Kft. · Budapest · NCT07746583

• Persistence on Guselkumab in Romanian adults with moderate-to-severe plaque psoriasis

  This study looks at how many adults with moderate-to-severe plaque psoriasis continue guselkumab treatment over two years in Romania.

  Recruiting at 20 sites Janssen Research & Development, LLC · Bârlad and 19 other locations · NCT07582783

• Higher-dose, less-frequent guselkumab versus the usual dose for moderate-to-severe plaque psoriasis in Chinese adults

  This will test whether a higher dose given less often of guselkumab works as well and is as safe as the usual dosing for Chinese adults with moderate-to-severe plaque psoriasis.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07532486

• HB0017 Injection safety and PK in low-weight adults at different injection sites

  This early-phase study tests a single subcutaneous HB0017 injection in healthy, low-weight adults and compares how the body processes the drug when injected at different sites.

  Recruiting Phase 1 Huabo Biopharm Co., Ltd. · Hangzhou, Zhejiang · NCT07920861

• MK-8644: first-in-human test in healthy people and people with psoriasis

  This early-phase study tests MK-8644 versus placebo in healthy volunteers and people with psoriasis to see if it is safe and tolerable.

  Recruiting Phase 1 Merck Sharp & Dohme LLC · Melbourne, Victoria · NCT07850310

• Long-Term Guselkumab Use in Adults with Inflammatory Bowel Disease

  This study looks at how long adults with Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.

  Recruiting Janssen Research & Development, LLC · Amiens · NCT07822529

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.